Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Public ClinicalTrials.gov record NCT04985604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Subprotocol of DAY101 Monotherapy for Patients With Recurrent, Progressive, or Refractory Solid Tumors With MAPK Pathway Aberrations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions or amplification.
Study identification
- NCT ID
- NCT04985604
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 23 participants
Conditions and interventions
Conditions
- Melanoma
- Solid Tumor
- CRAF Gene Amplification
- RAF1 Gene Amplification
- BRAF Gene Fusion
- BRAF Fusion
- CRAF Gene Fusion
- CRAF Fusion
- RAF1 Gene Fusion
- RAF1 Fusion
- Thyroid Cancer, Papillary
- Spitzoid Melanoma
- Pilocytic Astrocytoma
- Pilocytic Astrocytoma, Adult
- Non Small Cell Lung Cancer
- Non-Small Cell Adenocarcinoma
- Colorectal Cancer
- Pancreatic Acinar Carcinoma
- Spitzoid Malignant Melanoma
- Bladder Cancer
- Bladder Urothelial Carcinoma
- MAP Kinase Family Gene Mutation
- RAF Mutation
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 15, 2021 (Actual)
- Primary completion
- Jul 8, 2024 (Actual)
- Completion
- Jul 8, 2024 (Actual)
- Last update posted
- Oct 2, 2025
2021 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic | Los Angeles | California | 90025 | — |
| Hoag Health | Newport Beach | California | 92663 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32256 | — |
| Community North Cancer Center | Indianapolis | Indiana | 46250 | — |
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04985604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04985604 live on ClinicalTrials.gov.